{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:24:03Z","timestamp":1724804643207},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,27]]},"DOI":"10.7759\/cureus.67925","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T12:49:48Z","timestamp":1724762988000},"source":"Crossref","is-referenced-by-count":0,"title":["A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System Events for Trametinib"],"prefix":"10.7759","author":[{"given":"Xinyue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongrong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanrong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Encun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12651","article-title":"Vemurafenib\/dabrafenib and trametinib","volume":"80","author":"Rissmann R","year":"2015","unstructured":"Rissmann R, Hessel MH, Cohen AF. Vemurafenib\/dabrafenib and trametinib. Br J Clin Pharmacol. 2015, 80:765-7. 10.1111\/bcp.12651","journal-title":"Br J Clin Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2011.1015","article-title":"Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1\/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo","volume":"39","author":"Yamaguchi T","year":"2011","unstructured":"Yamaguchi T, Kakefuda R, Tajima N, Sowa Y, Sakai T. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1\/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol. 2011, 39:23-31. 10.3892\/ijo.2011.1015","journal-title":"Int J Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.03.004","article-title":"Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma","volume":"51","author":"Schadendorf D","year":"2015","unstructured":"Schadendorf D, Amonkar MM, Stroyakovskiy D, et al.. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur J Cancer. 2015, 51:833-40. 10.1016\/j.ejca.2015.03.004","journal-title":"Eur J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S72951","article-title":"Trametinib: A MEK inhibitor for management of metastatic melanoma","volume":"8","author":"Lugowska I","year":"2015","unstructured":"Lugowska I, Kose\u0142a-Paterczyk H, Kozak K, Rutkowski P. Trametinib: A MEK inhibitor for management of metastatic melanoma. Onco Targets Ther. 2015, 8:2251-9. 10.2147\/OTT.S72951","journal-title":"Onco Targets Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda T","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013, 10:796-803. 10.7150\/ijms.6048","journal-title":"Int J Med Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman KJ","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004, 13:519-23. 10.1002\/pds.1001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans SJ","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001, 10:483-6. 10.1002\/pds.677","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate A","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998, 54:315-21. 10.1007\/s002280050466","journal-title":"Eur J Clin Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"Dumouchel W","year":"1999","unstructured":"Dumouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat. 1999, 53:177-90. 10.1080\/00031305.1999.10474456","journal-title":"Am Stat"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)60868-x","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild A","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV, et al.. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (London, England. 2012, 380:358-65. 10.1016\/s0140-6736(12)60868-x","journal-title":"Lancet (London, England"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12124","article-title":"Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib","volume":"55","author":"Anforth R","year":"2014","unstructured":"Anforth R, Liu M, Nguyen B, et al.. Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib. Australas J Dermatol. 2014, 55:250-4. 10.1111\/ajd.12124","journal-title":"Australas J Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma","volume":"7","author":"Welsh SJ","year":"2015","unstructured":"Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol. 2015, 7:122-36. 10.1177\/1758834014566428","journal-title":"Ther Adv Med Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/277865-a-real-world-pharmacovigilance-study-of-the-fda-adverse-event-reporting-system-events-for-trametinib","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T12:49:52Z","timestamp":1724762992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/277865-a-real-world-pharmacovigilance-study-of-the-fda-adverse-event-reporting-system-events-for-trametinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.67925","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,27]]}}}